key: cord-0285611-ptd57hee
authors: Polinski, J. M.; Weckstein, A. R.; Batech, M.; Kabelac, C.; Kamath, T.; Harvey, R.; Jain, S.; Rassen, J. A.; Khan, N.; Schneeweiss, S.
title: Effectiveness of the Single-Dose Ad26.COV2.S COVID Vaccine
date: 2021-09-12
journal: nan
DOI: 10.1101/2021.09.10.21263385
sha: c4f461ed237f372f8297dca0c95ccdd236620fac
doc_id: 285611
cord_uid: ptd57hee

Background Randomized trials demonstrated efficacy of Ad26.COV2.S, a single-dose COVID-19 vaccine. Data assessing effectiveness in clinical practice and its stability over time since vaccination and against Delta variants are needed. Methods Using U.S. insurance claims data through July 2021, we identified individuals newly vaccinated with Ad26.COV2.S and up to 10 unvaccinated individuals matched exactly by age, sex, date, location, comorbidity index plus 17 COVID-19 risk factors via propensity score (PS) matching. We estimated Vaccine Effectiveness (VE) with 95% confidence intervals (CI) for observed COVID-19 and COVID-19-related hospitalization, nationwide and stratified by age, immunocompromised status, calendar time, and states with high incidence of the Delta variant. We corrected VE estimates for under-recording of vaccinations in insurance data. Results Among 390,517 vaccinated and 1,524,153 matched unvaccinated individuals, VE was 79% (95% CI, 77% to 80%) for COVID-19 and 81% (79% to 84%) for COVID-19-related hospitalizations. VE was stable over calendar time. Among states with high Delta variant incidence, VE during June/July 2021 was 78% (73% to 82%) for infections and 85% (73% to 91%) for hospitalizations. VE for COVID-19 was higher in individuals <50 years (83%; 81% to 85%) and lower in immunocompromised patients (64%; 57% to 70%). All estimates were corrected for under-recording; uncorrected VE was 69% (67% to 71%) and 73% (69% to 76%), for COVID-19 and COVID-19-related hospitalization, respectively. Conclusions These non-randomized data across U.S. clinical practices show high and stable vaccine effectiveness of Ad26.COV2.S over time before the Delta variant emerged to when the Delta variant was dominant.

With the global morbidity and mortality associated with the SARS-CoV-2 virus and the rapid spread of new variants, a temporal and geographical understanding of vaccine effectiveness (VE) in clinical practice is critical to inform public health recommendations. On February 27, 2021, the Food and Drug Administration issued an Emergency Use Authorization for Janssen's single dose COVID-19 vaccine, Ad26.COV2.S, 1 based on results from a double-blind, placebocontrolled randomized controlled trial (RCT), ENSEMBLE. 2 The overall efficacy estimate for preventing moderate-severe observed COVID-19 at least 14 days post-vaccination was 66% globally (74% US) and overall efficacy at least 28 days after vaccination was >84% against severe disease. 3 Despite the efficacy observed in the RCT, questions remain about generalizability to patients in clinical practice, and longer-term effectiveness. VE may be affected by disease variants, such as the Delta (B.1.617.2, AY.1, AY.2, AY.3) which emerged in late May 2021 and soon became the dominant variant across the U.S. by July. 4 A recent study showed the effectiveness of Ad26.COV2.S and other COVID-19 vaccines in ambulatory and inpatient care settings using data through June 22, 2021 . 5 However, the study included less than 1,500 subjects who had received Ad26.COV2.S vaccination which limits the interpretation of findings, its generalizability and any statements on the protection against Delta variants, in addition to general drawbacks of the test-negative study design. 6 As recommendations and guidelines change in response to a rapidly-changing disease landscape, population-based healthcare databases may observe VE, longer-term effectiveness, and COVIDrelated health outcomes with little delay. We utilized national U.S. claims data to assess the VE . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 12, 2021. ;  https://doi.org/10.1101/2021.09.10.21263385 doi: medRxiv preprint of Ad26.COV2.S in preventing breakthrough COVID-19 infections or COVID-19-related hospitalizations from March 2021 through July 2021. We specifically assessed VE during June and July in four U.S. states with early and high prevalence of the Delta variant. 7

We analyzed de-identified patient-level claims data from March 1, 2020 through July 31, 2021 submitted to insurance companies by U.S. providers of inpatient, outpatient, pharmacy, and laboratory services, and aggregated by HealthVerity. 8 The claims were anonymously linked across >70 different health data sources using a unique, encrypted and non-identifiable patient token derived from identifiable information known only to the provider. This token allows for cross-database longitudinal capture of diagnosis and procedure codes, COVID-19 laboratory test orders and results, and pharmacy dispensing information. 9 Cohorts for the current study were identified from a larger dataset of 160 million individuals with any record of lab orders, diagnoses, or treatments broadly related to COVID, or COVID vaccinations from December 2019 to July 2021. This study was approved by the New England institutional review board. These data have been used in previous studies. 10-12 They belong to third parties and cannot be shared publicly, however, upon reasonable request, researchers may get access to the data and analytics infrastructure for prespecified collaborative analyses.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint on the same day to up to 10 referent individuals with no evidence of vaccination with a COVID-19 vaccine at that time, with matching by location (3-digit ZIP), age within 4 years, sex, and general health status captured in a comorbidity score (Suppl. S1). 13 We required at least one medical and pharmacy claim during 365 days before cohort entry to ensure each individual's activity in the system. Those with observed COVID-19 or receipt of any COVID-19 vaccine during the 365 days before cohort entry were excluded (Suppl. S2).

Follow-up in each group started 14 days after cohort entry 14 and continued until the earliest of the occurrence of an outcome, receipt of any COVID-19 vaccine, death, or July 31, 2021.

The outcome of observed COVID-19 was defined by either recording of an in-or outpatient ICD-10-CM diagnosis code of U07.1 (85% of cases) in any position, and/or a recorded positive SARS-CoV-2 diagnostic PCR or nucleic acid amplification test result (15%). The co-primary outcome was COVID-19-related hospitalization, defined as any claim for an inpatient stay with a discharge diagnosis of COVID-19 or a recorded infection within 21 days before admission.

Participant characteristics, including a range of factors associated with severe COVID-19 disease, 15 were assessed during the 365 days before cohort entry (Suppl. S3 for all definitions):

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 12, 2021. ; https://doi.org/10.1101/2021.09.10.21263385 doi: medRxiv preprint chronic obstructive pulmonary disease, asthma, pulmonary fibrosis, cystic fibrosis, HIV, immunocompromised status after transplantation, liver disease, malignancies, cerebrovascular disease, chronic kidney disease, hypertension, obesity, heart failure, sickle-cell disease, thalassemia, diabetes mellitus, chronic neurologic conditions, and an overall comorbidity score. 13 We measured healthcare utilization intensity, a marker of patients' baseline health state and surveillance, including the number of pharmacy or medical claims in 365 days before cohort entry, and recent medical or pharmacy claims in the 60 days before.

To ensure balance between treatment groups in the absence of baseline randomization, and in addition to the 1:10 risk-set sampling by time, location, age, sex, and comorbidity score described above, we performed 1:4 propensity score (PS) matching with a caliper of ±0.01. The propensity score was estimated with logistic regression including all pre-exposure patient characteristics with no further variable selection. The resulting balance of characteristics between the vaccinated and PS-matched unvaccinated individuals was assessed by computing the absolute standardized difference for each covariate. 16 A value <0.10 indicates little imbalance between treatment groups and little effect on residual confounding. 17 We computed incidence rates per 1,000 person-years for vaccinated and unvaccinated participants and hazard ratios (HRs) with 95% confidence intervals (CI). 18 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. hereafter "high-Delta-incidence states"). 20 Given the expedited national vaccination effort, a sizable proportion of COVID-19 vaccinations were administered by employers, mass vaccination sites, pharmacies, and other settings where often no health insurance claims were submitted. The CDC reported that 57% of US residents 12 years and older were vaccinated as of July 22, 2021, while only 34% were recorded among the same people in our claims data, which confirms substantial under-recording (S4). As a result, it is highly likely that a substantial proportion of the unvaccinated group in claims data was in fact vaccinated and thus observed VE estimates will appear lower than indeed true. To compensate, we conservatively assumed 40% under-recording of vaccinations and applied a correction factor to all VE estimates using standard methods for correcting exposure misclassification. In sensitivity analyses, we varied the under-recording assumption from 0% to 70% (Tables S5 and   S6 ). 21 We conducted two additional sensitivity analyses to explore potential bias related to outcome capture and population sampling. First, we narrowed COVID-19 outcome definitions to require a positive nucleic acid amplification test result (Table S7) . Second, to minimize potential bias . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 12, 2021. ; https://doi.org/10.1101/2021.09.10.21263385 doi: medRxiv preprint related to non-differential sampling of our study population, we required all individuals to have some evidence of potentially COVID-related utilization before cohort entry (Table S8) .

All analyses were performed using the Aetion Evidence Platform v4.13 (including R v3.4.2), which has been scientifically validated by accurately repeating a range of previously-published studies 22 and by replicating 23 or predicting clinical trial findings. 24 All transformations of the raw data are preserved for full reproducibility and audit trails are available, including a quality check of the data ingestion process.

The study cohort included a total of 390,517 vaccinated U.S. individuals and 1,524,153 matched individuals with no recording of vaccination from March 1, 2021 through July 17, 2021 ( Figure   1 ). The two-stage matching by time, location, socio-demographic variables, and risk factors resulted in highly similar groups with absolute standardized mean differences ≤0.02 across all characteristics, well below 0.10 ( Table 1 ). In high-Delta-incidence states, 29,079 vaccinated individuals were similarly well-balanced when compared to 113,325 unvaccinated individuals, with all absolute standardized mean differences <0.03 (Table S2) , well below the 0.10 threshold.

Subgroups defined by age category, immunocompromised status, and geography were similarly well balanced (Tables S1 and S2). Table 2) . VE for observed COVID-19 was 79% (95% CI, 77% to 80%). Incidence rates of COVID-19-related hospitalization were 2.4/1,000 PY in vaccinated and . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 12, 2021. 9.1/1,000 PY in unvaccinated individuals resulting in a corrected VE of 81% (79% to 84%). VE for observed COVID-19 was higher in patients <50 years of age (83%; 81% to 85%); than in patients >50 (75%; 74% to 77%). Immunocompromised individuals had lower VE (64%; 57% to 70%) compared to non-immunocompromised individuals (79%; 78% to 81%). There was some regional variation in VE (Table S4) .

In high-Delta-incidence states, rates of observed COVID-19 were higher in both groups than in the national cohort, with incidence of 19.4/1,000 PY (vaccinated) v. 61.4/1,000 PY (unvaccinated) ( Table 2 ). In these states, VE for observed COVID-19 was 79% (75% to 83%) overall and 78% (73% to 82%) during June and July ( Table 2) , the months where Delta variant incidence was highest; for COVID-19-related hospitalization VE was 83% (74% to 89%) overall and 85% (73% to 91%) during June and July. VE within subgroups of the high-Delta-incidence states for both outcomes were similar to the national cohort with VE for COVID-19 of 81% in patients <50 years of age and 84% for COVID-related hospitalization in patients >50 years (Table S3) .

Examining the incidence of observed COVID-19 and COVID-19-related hospitalization as a function of time since vaccination, we observed sustained and stable VE starting 14 days after vaccination to a maximum of 152 days after vaccination (Figure 2) . Schoenfeld residual plots confirmed that the hazard ratio was constant over time (p=0.53) and that there was no VE reduction during the observable follow-up time (Figure S2 ).

An analysis by calendar months from March 2021 through July 2021 showed no meaningful variation in VE over calendar time. The VE for observed COVID-19 rose slightly until May to 81% (79% to 83%) and remained at a high level until the end of the follow-up period in July . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 12, 2021. ; https://doi.org/10.1101/2021.09.10.21263385 doi: medRxiv preprint (77%; 74% to 79%) when the Delta variant was spreading widely nationally (Figure 3a) . The monthly VE estimates for COVID-19-related hospitalization were equally stable (Figure 3b) . In the high-Delta-incidence states we saw no decline in the VE with respect to hospitalizations during the peak Delta variant months of June and July (Figure 3d) and some more variability in the VE for observed COVID -19 (Figure 3c) .

were similar to primary findings (Table S7) . When we required all participants to meet the additional criterion of COVID-related utilization before cohort entry, the corrected VE was reduced to 56% (53%, 60%) for COVID-19 and 57% (49%, 64%) for COVID-19-related hospitalization ( Table S8 ).

In U.S. clinical practice from March through July 2021, the single-dose Ad26.COV2.S vaccine showed effective protection against observed COVID-19 and COVID-19-related hospitalization with no evidence of reduced effectiveness over the maximum study duration. In states with early emergence and high incidence of the Delta variant, we found equally high and sustained vaccine effectiveness (VE). These results provide evidence that the VE observed in the ENSEMBLE trial translates into clinical practice, lasts over at least 152 days post-vaccination, and remains effective amid high Delta variant incidence. Although we saw high VE in the US through July 2021, when the delta variant was dominant per CDC sequence data, we did not have sequencespecific information in our real-world data, hence we do not know with certainty the delta variant-specific vaccine effectiveness. We plan to update this Ad26.COV2.S VE study with monthly data refreshes to expeditiously identify any changes in VE. 25 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 12, 2021. ; https://doi.org/10.1101/2021.09.10.21263385 doi: medRxiv preprint VE varied by age subgroup, with patients <50 having a higher VE than those ≥50 years of age. This is consistent with the age-dependent variation in VE observed in the ENSEMBLE trial and with evidence on the immune response to the BNT162b2 vaccine by age. 3, 26, 27 Results from our population-based study suggest that immunocompromised patients who are vaccinated with a single dose have slightly reduced yet still substantial protection against COVID-19 and COVID-19-related hospitalizations for at least 150 days.

Although lacking baseline randomization, vaccinated and unvaccinated individuals were exactly matched by age, sex, comorbid-risk, calendar date, and location, followed by additional PS- This study is mainly based on the data that flows from U.S. healthcare providers to insurance companies for reimbursement and are available sooner than traditional adjudicated ("closed") insurance claims. While other studies have used these "open" claims data to study 10 the data (a) include no specific listing of who is enrolled in an insurance plan, making the denominator challenging to precisely estimate at a given point in time and (b) potentially lack complete capture of all longitudinal healthcare interactions for any given patient. Our study . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 12, 2021. ; https://doi.org/10.1101/2021.09.10.21263385 doi: medRxiv preprint therefore required the occurrence of provider-based medical and pharmacy claims unrelated to COVID during baseline to restrict our population to those with more complete outcome capture, making it unlikely that there is differential capture of information between the groups. Further, the lack of meaningful month-to-month changes in VE demonstrating sustained protection of the vaccine is unlikely to be affected by this.

As a result of mass vaccination efforts by a range of public and private organizations, where health insurance information may not have been required, collected or submitted, a substantial fraction of COVID-19 vaccine administrations were not recorded in insurance data. 28 Given the under-recording of COVID-19 vaccinations in insurance claims data which leads to an underestimation of the true effect size, we empirically estimated the level of under-recording in our data source (Suppl. S4) and applied standard correction methods to all VE estimates. 29 Even if one would falsely assume 0% under-recording and completely disregard the necessary correction, the VE estimates would decline by about 10 percentage points as illustrated in Tables S5 and S6. The resulting biased and underestimated VE of 69% (67% to 71%) for infections and 73% (69% to 76%) for hospitalizations demonstrates substantial vaccine protection.

Assuming such outcome misclassification would be non-differential regarding the vaccination status, this would likely lead to an underestimation of the reported VE on observed COVID-19 but would not affect the VE for COVID-related hospitalizations. 29 Additionally, COVID-19 outcomes captured with ICD-10 diagnosis codes in claims data may indicate more severe cases requiring physician consult as opposed to individuals with asymptomatic or mild to moderate disease who may be less likely to seek professional care and generate claims. 31,32 While it is . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 12, 2021. ; https://doi.org/10.1101/2021.09.10.21263385 doi: medRxiv preprint unclear how exactly the infection severity definition compares with definitions used in RCTs, we suggest comparing our findings with the RCT's severe, or moderate to severe, definition. 2 Consistency of VE results across sensitivity analyses with lab-only outcome definitions provides further evidence for the robustness of our primary results (Table S7) .

Finally, VE estimates were directionally consistent but lower in magnitude than primary results in sensitivity analyses requiring all vaccinated and unvaccinated individuals to have evidence of COVID-related utilization before cohort entry (Table S8) . While this sensitivity analysis may reduce potential selection bias introduced during the data extraction stage by picking sicker unvaccinated individuals, it may also include more individuals with undiagnosed COVID before cohort entry, and thus may together represent the lower bound of VE.

These non-randomized population-based data from clinical practice in the US demonstrate the high and stable effectiveness of Ad26.COV2.S across high-risk patient subgroups and in geographic areas of high Delta variant incidence. As the COVID-19 pandemic continues and variants evolve the observed effectiveness may change in the future as new variants emerge. Our data and data to be generated over the coming months using this system of claims data contribute important and otherwise unattainable evidence to policymakers, physicians, and patients.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint 

Observed COVID-19

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 12, 2021. ; https://doi.org/10.1101/2021.09.10.21263385 doi: medRxiv preprint

Meeting Presentation -Emergency Use Authorization (EUA) Application for Ad26

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE). clinicaltrials.gov [Internet] (NCT04505722). Available from

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

COVID Data Tracker Monitoring Variants

Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings

Covid-19 Vaccine Effectiveness and the Test-Negative Design

Centers for Disease Control and Prevention

Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection

Renin-Angiotensin-Aldosterone-System inhibitor use in patients with observed COVID-19 and prevention of serious events: a cohort study in commercially insured patients in the US

Diagnosis-wide analysis of COVID-19 complications: an exposure-crossover study

A combined comorbidity score predicted mortality in elderly patients better than existing scores

Evaluation of COVID-19 vaccine effectiveness: Interim Guidance

Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older

Metrics for covariate balance in cohort studies of causal effects

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples

Regression Models and Life-Tables

Nonparametric Estimation from Incomplete Observations

The Delta variant is driving up COVID rates. See the states where it's most prevalent

Modern epidemiology

Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study

Emulating Randomized Clinical Trials with Nonrandomized Real-World Evidence Studies: First Results from the RCT DUPLICATE Initiative

Using real-world data to predict findings of an ongoing phase IV cardiovascular outcome trial: cardiovascular safety of linagliptin versus glimepiride

Sequential Monitoring of the Comparative Effectiveness and Safety of Dabigatran in Routine Care

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

secretary-becerra-letter-to-issuers-providers

Available Age, mean (sd)

Chronic kidney disease

Moderate-to-severe asthma

Type 2 diabetes

Gagne combined comorbidity score, mean (sd)

3%) 338,650 (22.2%) -South; n (%) 162,865 (41.7%) 636,225 (41.7%) -West; n (%)

only*** 110 4,491 24

Unless otherwise noted, incident rates are reported per 1,000 person-years and vaccine effectiveness (VE) estimates (observed and corrected) are calculated using hazard ratios with reported 95% confidence interval limits. Corrected VE estimates are adjusted for under-recording of vaccinations in claims data using the approach described in

Delta-incidence States (early Delta states) include

and Missouri) with high prevalence of the Delta variant of concern, incident rate ratios (IRR) after PS matching are reported instead of hazard ratios and VE is estimated using (1-IRR)x100 for patients contributing follow-up time from

The authors thank the following team members for critical feedback during the development of the study protocol and/or review of findings: Deb Ricci (Janssen), Khaled Sarsour (Janssen), Jennifer Hayden (Janssen), Xiaoying Wu (Janssen), Sophia Gallucci (Aetion), Jen Thorburn (Aetion), Michelle Skornicki (Aetion), Rouhi Abdollahi (Janssen), Kristopher Standish (Janssen), Lev Demirdjian (Janssen), Daniel Backenroth (Janssen), and Jerry Sadoff (Janssen). We would like to also thank Andrew Kress (HealthVerity) for his support with technical data questions, and the many people involved in the technical implementation process and independent quality control, Julie Schiffman (Aetion), Hanaya Raad (Aetion), Julia Pitino (Aetion), Lexie Rubens (Aetion), and Tancy Zhang (Aetion).